NKTR
Nektar Therapeutics
$81.89
-1.78%
2026-05-08
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Key Fundamentals
Forward P/E
-7.47
EPS (TTM)
$-9.73
ROE
-217.9%
Revenue Growth (YoY)
-25.3%
Profit Margin
-297.1%
Debt/Equity
165.76
Price/Book
18.62
Beta
1.25
Market Cap
$2.77B
Avg Volume (10D)
871K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$109.00
60D Low
$62.00
Avg Volume
1.1M
Latest Close
$81.89
Get breakout alerts for NKTR
Sign up for Breakout Scanner to receive daily notifications when NKTR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Nektar Therapeutics (NKTR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors NKTR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NKTR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.